RXRX Q4 2023 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-22.3% YoY

Gross Profit

$743,0007.0% margin

Operating Income

-$99M-931.2% margin

Net Income

-$93M-875.3% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+5.2%

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$76M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$654M

Total Liabilities

$190M

Stockholders' Equity

$463M

Cash & Equivalents

$392M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$14M	-22.3%
Gross Profit	$743,000	$3M	-73.8%
Operating Income	-$99M	-$61M	-62.2%
Net Income	-$93M	-$57M	-61.8%

Revenue Segments

License and Service

$11M98%

Grant

$267,0002%